How do I compare CPC and QYB on lead time to the United Kingdom?

Conditions: CPC · QYB · the United Kingdom.

These are treated as interchangeable and I do not think they are.

If both are acceptable I would like to know that, so I can stop thinking about it.

What is the actual trade-off, and does it matter at the scale I am working at?

The relevant point is that two competent laboratories disagree by half a per cent on identical material, which is larger than most of the differences people argue about.

Submitting to different laboratories introduces a method difference that commonly exceeds the supplier difference. Gradient slope alone can move a reported purity figure by a per cent in either direction.

Compare documentation on a fixed checklist rather than by impression: lot specificity, method section, chromatogram availability, quantified content, water and counter-ion figures, and whether the code is on the vial.

Gradient slope, column chemistry and detection wavelength all affect the reported purity figure, which is why the method section is the part that makes results comparable.

Name the laboratory and the dates or the comparison cannot be reproduced.

edited 9 May 2025 by forty_two_c — fixed an arithmetic slip in the third paragraph

The honest answer is that most claimed differences between reputable suppliers are inside inter-laboratory noise.

Lead time and lane behaviour are supplier properties too and are easier to compare than analytical ones, because they need no laboratory at all.

Stated carefully, publish the method with the result. A comparison without the laboratory named and the submission dates given is not reproducible by anyone.

Inter-laboratory spread on identical peptide material is routinely half a per cent to a per cent by RP-HPLC, which is the noise floor for any cross-laboratory comparison.

One laboratory, one method, one submission. Otherwise it is not a comparison.

edited 9 May 2025 by two_point_four — added the placebo-arm figures

Start by asking what you are optimising for, because cost per milligram, documentation depth and lead time do not have a common winner.

Cost per milligram of actual peptide is the honest price comparison, which means dividing by measured content rather than by label claim.

Specifically, sample size matters. One order each is an anecdote about six vials; three orders each over a year is the beginning of a comparison.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Use a fixed documentation checklist rather than an impression.

A single member running three suppliers on one method is worth more than thirty members running one supplier each.

Content is the more discriminating measurement than purity for supplier comparison, because purity clusters tightly among competent suppliers and content does not.

The ratings on this site are a community opinion average on a ten-point scale and are not reconciled with any other community's figures.

Comparisons drawn from different laboratories at different times are weaker evidence than most people treat them as.

Price per milligram of measured peptide, not per milligram of label claim.

Answering this needs the axis. A supplier that is best on paperwork and a supplier that is best on price are both correct answers to different questions.

To compare properly: order the same compound at the same nominal strength from each supplier, submit all samples to the same laboratory in the same submission if possible, and ask for the same test set on each.

Content assay results across the published datasets vary considerably more between suppliers than purity does, which makes content the more discriminating axis.

No supplier on this site pays for its position, and the storefront links are marked nofollow and sponsored.

Compare content, not purity. Purity clusters and content does not.